Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) have received a consensus recommendation of “Buy” from the fourteen research firms that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $175.60.

GWPH has been the topic of a number of recent analyst reports. BidaskClub upgraded shares of GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a report on Thursday, January 17th. Morgan Stanley reiterated a “buy” rating on shares of GW Pharmaceuticals PLC- in a research note on Tuesday, April 9th. Zacks Investment Research upgraded shares of GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research note on Wednesday, February 6th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $185.00 target price on shares of GW Pharmaceuticals PLC- in a research note on Wednesday, February 27th. Finally, JPMorgan Chase & Co. initiated coverage on shares of GW Pharmaceuticals PLC- in a research note on Wednesday, January 2nd. They issued an “overweight” rating and a $134.00 target price for the company.

In other news, CEO Justin D. Gover sold 23,400 shares of GW Pharmaceuticals PLC- stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $14.01, for a total transaction of $327,834.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Geoffrey W. Dr Guy sold 1,200,000 shares of GW Pharmaceuticals PLC- stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $14.69, for a total transaction of $17,628,000.00. Following the transaction, the insider now directly owns 8,465,528 shares of the company’s stock, valued at $124,358,606.32. The disclosure for this sale can be found here. Insiders have sold a total of 1,895,496 shares of company stock valued at $27,538,565 over the last three months. 5.50% of the stock is currently owned by insiders.

Several large investors have recently bought and sold shares of the company. FMR LLC increased its holdings in GW Pharmaceuticals PLC- by 62.1% during the third quarter. FMR LLC now owns 104,520 shares of the biopharmaceutical company’s stock valued at $18,055,000 after buying an additional 40,044 shares during the last quarter. LPL Financial LLC boosted its position in shares of GW Pharmaceuticals PLC- by 11.4% in the third quarter. LPL Financial LLC now owns 6,799 shares of the biopharmaceutical company’s stock worth $1,174,000 after purchasing an additional 698 shares during the period. Capital International Investors bought a new position in shares of GW Pharmaceuticals PLC- during the third quarter worth $32,475,000. Mackenzie Financial Corp boosted its position in shares of GW Pharmaceuticals PLC- by 26.1% during the third quarter. Mackenzie Financial Corp now owns 6,423 shares of the biopharmaceutical company’s stock worth $1,110,000 after acquiring an additional 1,331 shares during the last quarter. Finally, Brown Brothers Harriman & Co. bought a new position in shares of GW Pharmaceuticals PLC- during the third quarter worth $281,000. 79.42% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:GWPH traded down $3.54 during trading on Monday, reaching $164.28. The stock had a trading volume of 20,613 shares, compared to its average volume of 348,497. GW Pharmaceuticals PLC- has a one year low of $90.14 and a one year high of $182.23. The stock has a market capitalization of $5.06 billion, a P/E ratio of -15.57 and a beta of 2.80. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.34 and a current ratio of 6.66.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Featured Story: How to Profit and Limit Losses With Stop Orders

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.